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Abstract
Background: L’Hermitte’s sign (LS) after chemoradiotherapy for head and neck cancer appears related to higher
spinal cord doses. IMRT plans limit spinal cord dose, but the incidence of LS remains high.
Methods: One hundred seventeen patients treated with TomoTherapy™ between 2008 and 2015 prospectively
completed a side-effect questionnaire (VoxTox Trial Registration: UK CRN ID 13716). Baseline patient and treatment
data were collected. Radiotherapy plans were analysed; mean and maximum spinal cord dose and volumes
receiving 10, 20, 30 and 40 Gy were recorded. Dose variation across the cord was examined. These data were
included in a logistic regression model.
Results: Forty two patients (35.9%) reported LS symptoms. Concurrent weekly cisplatin did not increase LS risk (p =
0.70, OR = 1.23 {95% CI 0.51–2.34}). Of 13 diabetic participants (9 taking metformin), only 1 developed LS (p = 0.025,
OR = 0.13 {95% CI 0.051–3.27}). A refined binary logistic regression model showed that patients receiving unilateral
radiation (p = 0.019, OR = 2.06 {95% CI 0.15–0.84}) were more likely to develop LS. Higher V40Gy (p = 0.047, OR = 1.06
{95% CI 1.00–1.12}), and younger age (mean age 56.6 vs 59.7, p = 0.060, OR = 0.96 {95% CI 0.92–1.00}) were
associated with elevated risk of LS, with borderline significance.
Conclusions: In this cohort, concomitant cisplatin did not increase risk, and LS incidence was lower in diabetic
patients. Patient age and dose gradients across the spinal cord may be important factors.
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Background
With contemporary techniques, transverse myelitis follow-
ing radical radiotherapy (RT) for head and neck cancer
(HNC) is extremely rare. The QUANTEC paper of 2010
quotes a risk of < 1% at 54Gy with conventional fraction-
ation [1], and recent randomised trials have mandated max-
imum spinal cord (SC) doses much lower than this [2, 3].
However, milder spinal cord toxicity in the form of L’Her-
mitte’s sign (LS) may be more prevalent.
LS is characterised by electric-shock sensations down
the spine and into limbs on neck movement (particularly
flexion). It is a well-recognised symptom of demyelinating
conditions such as Multiple Sclerosis (MS) [4], and can
also occur as a side effect of radiation to the cervical or
thoracic spinal cord [5]. The mechanism is believed to be
transient inhibition of oligodendrocyte proliferation lead-
ing to reversible demyelination [6, 7]. LS usually develops
in the first few months after radiotherapy, and seldom
lasts more than 6 months [7–9], but can be unpleasant
and distressing for patients. No clear link between radio-
genic LS and progressive irreversible myelitis has been
established, although delayed radiation-induced myelop-
athy causing paralysis may be preceded by LS [9].
Historical series, in which patients were treated with
conformal, field-based techniques, report a risk of LS
following RT for HNC between 3 and 13% [9–11]. More
recent work on LS following Intensity Modulated RT
(IMRT) for thoracic and head and neck malignancy de-
scribes an incidence between 15 and 29% [5, 12, 13].
Since IMRT permits superior sparing of critical organs
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at risk (OARs), and given our previous understanding of
the dose-response relationship of the spinal cord [1, 14],
these results are surprising. Recent research has indi-
cated that younger age and higher maximum dose are
risk factors, and inferred that concomitant chemother-
apy may also be implicated [13, 15].
IMRT can generate steep dose gradients in order to
adequately treat target volumes, whilst sparing OARs
such as the SC. This often results in inhomogeneous
dose distributions across OARs, and work on rat models
has suggested that such inhomogeneity may be a risk
factor for LS [16]. Whilst some clinical data appears to
support this notion [12], no convincing evidence of a
‘bath and shower’ effect has yet been seen [13].
We sought to examine the link between radiation
dose, comorbidities, and concomitant systemic therapy
and the subsequent development of LS using a logistic
regression model, in a cohort of patients with HNC re-
cruited to the VoxTox study.
Methods
Study design & patient selection
VoxTox is a longitudinal observational study to collect
toxicity data for patients undergoing image-guided
IMRT [17]. It received National Research Ethics Service
(NRES) Committee East approval in February 2013 (13/
EE/0008) and is part of the UK Clinical research net-
work Study Portfolio (UK CRN ID 13716).
Adults undergoing curative RT with daily image guid-
ance (IG) for histologically confirmed HNC are eligible
for the broader study. This work included patients with
squamous cell carcinomas (SCC’s) and salivary gland tu-
mours (SGT’s) undergoing treatment to the primary site
and neck with a minimum of 30 fractions. Prescription
doses of 60Gy and above were permitted, and for pa-
tients to be included, a minimum of ipsilateral nodal
levels II and III needed to be included in the neck CTV.
As new LS beyond the first year is rare [9], a minimum
follow up of 1 year was mandated. The following factors
were regarded as exclusion criteria; incomplete baseline
screening of past medical history, shorter fractionation
schedules (fraction size > 2.17Gy), primary site radiation
only, documented neurological comorbidity, non-
specific neurological symptoms (e.g. numbness and tin-
gling) at baseline, and insufficient follow up.
Patient treatment
All patients in this study underwent helical IMRT on the
TomoTherapy HiArt™ system with daily IG [18]. Immobil-
isation was with a thermoplastic shell, and simulation per-
formed on a planning-CT with 3 mm slices. Diagnostic
imaging including MRI and PET-CT was rigidly co-
registered to aid contour definition. A 3-dose, 30 fraction
technique was used for SCCs. Gross primary and nodal
disease CTV’s received 65Gy, high-risk elective regions
60Gy and lower risk neck CTVs 54Gy in line with recent
trial protocols [2]. Post-operative patients (both SCC’s and
SGT’s) underwent adjuvant RT following surgery and re-
ceived 60Gy in 30 fractions to primary site and elective
nodal regions depending on risk. A PTV margin of 5 mm
was used for all target volumes. The SC (not canal) was
contoured as an OAR, with a 3 mm PRV margin. A max-
imum dose objective of 46Gy and absolute dose constraint
of 50Gy to the SC PRV were defined.
Fit patients (KPS ≥ 80) up to 70 years old with Stage III-
IV SCC received concomitant weekly cisplatin (40 mg/m2),
or cetuximab (400 mg/m2 loading dose, 250 mg/m
2 weekly
dose) if specific contraindications to cisplatin existed [19].
Chemotherapy records were retrospectively accessed to
define how many cycles of systemic therapy patients
received. Baseline characteristics are listed in Table 1.
Toxicity assessment
Using both the CTCAE v4.03, and LENT-SOM(A)
scales, patients had toxicity assessments undertaken at
baseline, and 3, 6 and 12 months post-treatment
[20, 21]. Interviews were undertaken by the study re-
search radiographer. Patients were asked about symp-
toms of LS, and responses were logged digitally at
interview into a database within MOSAIQ® (Elekta,
Stockholm, Sweden) care management software.
CTCAE v4.03 was used for the primary analysis. Symp-
toms consistent with LS qualified as Grade 1 myelitis. On
this basis, patients were categorised as either having LS or
not. Previous studies show that the average duration of LS
is 4–6 months [10, 11, 13]. We therefore took a single
positive response as sufficient to define patients as having
developed LS. The LENT-SOM(A) scale was used to grade
severity of symptoms from 0 to 4, and this data informed
a secondary ordinal analysis. The relevant question from
the clinical reporting form is found in supplementary ma-
terials (Additional file 1: Figure. S1).
Spinal cord dosimetry
Planning CT images, structure sets and dose cubes were
reloaded into RT contouring software ProSoma v3.3
(MedCom GmbH, Darmstadt, Germany). To minimise
bias from inter-observer contouring variability, the
spinal cord was re-contoured for all cases by one obser-
ver (DJN). To replicate the methodology of a similar
study [13], two separate volumes were created; ‘whole
cord’ and ‘short cord’ (Fig. 1a). Whole cord was defined
by foramen magnum superiorly, and inferior extent of
the planning scan, usually carina, inferiorly. The short
cord volume was created by deleting slices caudal to the
most inferior PTV slice. ProSoma was used to compute
cumulative DVH’s for both structures. The whole cord
volume was used to calculate the maximum point dose
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to the spinal cord (Dmax), and the minimum dose to the
2cm3 of the spinal cord receiving the highest dose (D2cc)
, as well as the absolute volumes receiving 10, 20, 30 and
40Gy respectively (V10Gy, V20Gy, V30Gy, V40Gy) [13]. The
short cord volume was used to calculate mean and
median dose to the cervical cord, and relative volumes
receiving 10, 20, 30 and 40Gy respectively (V10%, V20%,
V30%, V40%).
To investigate the effect of dose inhomogeneity [12, 13],
DVH data for short cord volumes were used to calculate
homogeneity index, defined as (D2% - D98%)/D50% [22]. An
example patient with LS, and a significant axial dose gra-
dient across the spinal cord, is shown in Fig. 1b.
Statistics
A refined logistic regression model was developed in
three steps: 1) Univariate analyses 2) Logistic regression
model 3) Refined logistic regression model. Univariate
relationships between LS incidence and baseline parame-
ters, chemotherapy and radiotherapy data were analysed
using Fisher’s Exact test if they were binary, student’s t-
test if data were parametric (determined by Shapiro-
Wilk test), and Mann-Whitney U test if not. Odds ratios
with 95% confidence intervals were calculated for inde-
pendent variables. Estimates of the confidence intervals
between medians are shown in Table 2 [23]. A receiver
operator characteristic (ROC) curve analysis was used to
assess the relationship between number of cycles of cis-
platin received, and the incidence of LS.
Variables were included in a regression model based
on three criteria: (i) biological plausibility and evi-
dence from previous studies, (ii) collinearity statistics
to reduce confounding, (iii) univariate analysis associ-
ation at the p < 0.15 level. Automated subset selection
algorithms were not used, nor was selection based
solely on univariate statistics, as these methods may
conflate chance effects and reduce the reliability of
models in biological systems [24]. Instead variables
that fit the three criteria above were used to produce a
regression model. Finally, the model was refined by
removing all variables where p > 0.15 and recalculating
the regression model. Statistical analysis was
Table 1 Patient characteristics univariate analysis
Non-LS (n = 75) LS (n = 42) Odds Ratio (95% CI) p-value
Patient characteristics
Mean age ± SD 59.7 ± 8.7 56.6 ± 11.4 0.96 (0.93–1.01) 0.1a
-Difference (95% CI) 3.1 (− 0.9 to 7)
-Age range 34–79 38–78
Male 64 (85%) 33 (79%) 0.63 (0.3–2.2) 0.4b
-Difference (95% CI) −6.7% (−21.5 to 8.1)
Tumour characteristics
SCC 68 (90.7%) 36 (85.7%) 0.62 (0.3–2.6) 0.2b
-Oropharynx 43 (57.3%) 26 (61.9%) > 0.9
-Oral Cavity 9 (12.0%) 2 (4.8%) 0.4
-Larynx 8 (10.6%) 2 (4.8%) 0.4
-CUP 6 (8.0%) 1 (2.4%) 0.3
-Hypopharynx 1 (1.2%) 2 (4.4%) > 0.9
-Nasopharynx 1 (1.2%) 3 (6.7%) > 0.9
Salivary gland 7 (9.3%) 6 (14.3%) 1.6 (0.4–3.9) > 0.9
Treatment plan
≥65 Gy prescribed 60 (80.0%) 31 (73.8%) 0.71 (0.4–2.1) 0.7b
Unilateral radiotherapy 20 (26.7%) 18 (42.8%) 2.06 (0.6–3.0) 0.07b
Cisplatin prescribed 39 (52.0%) 26 (61.9%) 1.5 (0.6–2.6) 0.3b
-Cisplatin received 39 (52.0%) 24 (57.1%) 1.23(0.5–2.3) 0.7b
Cetuximab prescribed 8 (10.7%) 2 (4.8%) 0.42 (0.1–3.4) 0.3b
No chemotherapy 28 (37.3%) 14 (33.3%) 0.84 (0.4–2.1) 0.8b
Neurological Risk Factors
Hypertension 25 (33.3%) 8 (19.0%) 0.47 (0.3–1.79) 0.1b
Diabetes 12 (16.0%) 1 (2.4%) 0.13 (0.1–3.3) 0.03b
Abbreviations: CI – confidence interval, SD – standard deviation, CUP – cancer of unknown primary aStudent’s t test, bFisher’s exact test
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performed using IBM SPSS v23, and R statistical soft-
ware (R Notebook, R version v3.4.0, R Foundation for
Statistical Computing).
Results
One hundred seventeen patients were included in the
final analysis, and 42 patients (35.9%) reported LS symp-
toms at least once: 29 reported Grade 1 LS, 11 Grade 2,
two people had Grade 3 symptoms, and none reported
Grade 4. Mean onset of LS symptoms was 5.4 months;
median duration was 6 months.
Univariate analyses
Cisplatin prescription (as a binary variable) was not as-
sociated with LS development (Table 1). As cisplatin was
administered weekly, ROC curve analysis was used to
test the hypothesis that patients receiving a greater cu-
mulative dose might be at greater risk, despite the ab-
sence of a relationship as a binary variable (Fig. 2). This
confirmed that the number of cycles of cisplatin received
had no impact on incidence of LS (ROC curve AUC = 0.
53, 95% CI 0.43–0.63). However, younger patients were
more likely to get cisplatin, (mean age 56.1 +/− 7.8 vs
61.7 +/− 11.1, p = 0.0017), whilst diabetic and hyperten-
sive patients were less likely to receive the drug (p = 0.
0036 and p = 0.017 respectively). Univariate analysis
showed possible relationships between LS and all 3 fac-
tors (Table 1). Therefore, to mitigate the potential for
these factors confounding and masking a real effect from
concomitant chemotherapy, cisplatin was included in
the first iteration of the logistic regression model.
Unilateral neck treatment tends towards significance on
univariate analysis, despite mean Dmax being lower in pa-
tients treated unilaterally than those undergoing bilateral
neck irradiation (35.4 vs 36.9Gy). This difference did not
reach significance at the 5% level (p= 0.08, Additional file 1:
Fig. 1 Spinal cord dosimetry a ‘whole cord’ shown in blue, ‘short
cord’ in pink. b axial dose gradient across the cervical cord; max. Left
- right gradient 8.3Gy (36.9–28.6Gy). Dose wash; 95% isodose for
60Gy (57.9Gy) dark red, 50Gy light red, 45Gy orange, 40Gy amber,
35Gy green, 30Gy light blue, 25Gy royal blue
Table 2 Univariate analysis of SC Dose parameters and LS incidence
Non-LS (n = 75) LS (n = 42) Difference (95% CI) p value (2-tailed)
Dmax 36.4 ± 4.7 36.6 ± 5.3 0.27 (−1.6–2.1) 0.8
a
D2cc 33.1 ± 4.8 33.0 ± 5.6 0.10 (− 1.9–2.1) 0.9
a
Dmean 29.4 ± 5.4 28.4 ± 4.9 1.0 (−0.9–2.9) 0.3
a
HI 0.48 ± 0.27 0.57 ± 0.22 0.093 (0.002–0.2) 0.05a
V10Gy 14.3 ± 3.3 14.0 ± 2.9 0.35 (− 0.8–1.5) 0.6
a
V20Gy 12.4 ± 3.7 11.5 ± 3.4 0.90 (− 0.4–2.2) 0.3
a
V30Gy 7.6 (1.9–11.3) 4.9 (1.6–8.5) 2.7 (− 0.3–5.7) 0.1
b
V40Gy 0 (0–0.03) 0 (0–0.15) 0 (0–0) 0.9
b
V10% 100 (100–100) 100 (100–100) 0 (0–0) 0.7
b
V20% 99.5 (91.2–100) 96.4 (79.9–99.3) 3.1 (− 1.1–7.4) 0.02
b
V30% 61.60(14.5–86.8) 41.6 (13.9–70.6) 20 (−2–41) 0.1
b
V40% 0 (0–0.19) 0 (0–1.16) 0 (0–0) 0.9
b
Abbreviations: CI – confidence interval, HI- homogeneity index aMean ± SD and Student’s t test, bMedian, Interquartile range and Mann Whitney U test
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Figure S2). Homogeneity index was slightly higher in pa-
tients with LS (p= 0.049) and significantly higher in patients
receiving unilateral treatment (p= 0.0004) (Table 2, Fig. 3).
Both mean and maximum SC dose was similar in pa-
tients with and without LS (Table 2). Only 28.6% of pa-
tients who developed LS, but also 26.7% of patients who
did not, had SC Dmax ≥ 40 Gy (p = 0.8). Some dose pa-
rameters (V30Gy, V40Gy, V10%, V20%, V30%, V40%) were not
normally distributed (because they were mostly 0 or 100
– Additional file 1: Figure S3) and could not be trans-
formed to fit a normal distribution. Using the Mann
Whitney U test three dose parameters were associated at
the p < 0.15 level; V20%, V30%, and V30Gy. The latter two
were excluded to avoid multi-collinearity (Additional file 1:
Figure S4 and Table S1).
Previous studies show that higher SC dose is more
likely to cause LS or myelitis [7, 11, 15], with absolute or
partial volumes over 40 Gy seemingly most predictive
for LS [13]. SC doses in our series are substantially lower
than these studies, and the absence of a relationship be-
tween V40Gy/V40% and LS on univariate analysis (p = 0.85
and 0.86 respectively) may have been influenced by the
low proportion of patients receiving ≥40 Gy (27%).
Those that did had only small volumes of SC receiving
40 Gy (mean 1.44cm3). V40Gy metrics were therefore
included in the logistic regression model, to directly
compare with previous work in the field, to account for
possible bias on univariate analysis, and to strengthen
our initial assertion if univariate analysis results were
reproduced.
Fig. 2 Number of cycles of cisplatin received vs incidence of LS a number of cisplatin cycles received by patients with and without LS (absolute
numbers above bars). b - Receiver Operator Characteristic curve - number of cisplatin cycles received for prediction of LS (AUC = 0.525, 95% CI =
0.416 to 0.634)
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Logistic regressions
A binary logistic regression model (LS vs Non-LS) was
produced - Table 3. Age, unilateral vs bilateral radi-
ation (laterality), homogeneity index, diabetes, and
hypertension were included as they trended towards
significance on univariate analysis (p < 0.15, Tables 1
and 2). Cisplatin, V20% and V40% were included as de-
scribed. The model was refined by removing variables
with a p value over 0.15. This refined model found 3
predictors of LS with a pre-defined α < 0.05: unilateral
neck radiation, higher percentage volumes receiving
40 Gy or more, and absence of diabetes.
An ordinal regression (highest grade of LS re-
ported as the dependent variable) was also under-
taken to investigate an association with more severe
symptoms (Additional file 1: Table S2). This sug-
gested younger age is also a significant predictor of
LS (p = 0.031).
It is possible that by using relative dose-volume pa-
rameters in the primary analysis, small differences in
absolute volume were magnified (V40Gy range; 0 to 8.
2 cc, V40% range; from 0 to 66.4%). To account for this
effect, the analysis was repeated using V20Gy and V40Gy
instead of V20% and V40% (Additional file 1: Tables S3
and S4). The outcome was very similar; in this model
predictors of LS included younger age (p = 0.028), uni-
lateral treatment (p = 0.042), higher absolute volumes
receiving 40 Gy (p = 0.025), and absence of diabetes (p
= 0.033). V20Gy was predictive in the ordinal regression
(p = 0.021).
Discussion
This is the largest prospective study of L’Hermitte’s
syndrome in HNC patients in the era of IG-IMRT. LS in-
cidence in our cohort is higher than previously reported
(3.6–29%) [5, 11–13, 15], although mean onset and dur-
ation of symptoms were similar. The high incidence may
be due to its prospective nature, and the fact that a single
positive response classified patients as having LS. As LS is
transient [9], we believe this definition is justified. Further-
more, these data come from a large, prospectively evalu-
ated cohort of patients treated with a homogeneous
protocol including daily IG and positional correction; thus
the observed difference in LS incidence is credible.
Fig. 3 Dose inhomogeneity in patients with and without LS a Box and whisker plots showing higher homogeneity index in LS patients b higher
homogeneity index in patients receiving unilateral neck radiation.
Table 3 Binary logistic regression with LS vs Non-LS as the
dependent variable
Independent
Variable
Logistic regression
coefficient
Regression
p value
Odds Ratioa
(95% CI)
Original model
Age −0.034 0.1 0.97 (0.9–1.0)
Laterality −1.037 0.05 0.35 (0.13–1.0)
Diabetes 2.166 0.06 8.7 (0.9–83)
Hypertension 0.384 0.5 1.5 (0.5–4.3)
Cisplatin −0.384 0.4 0.68 (0.3–1.8)
V20% −0.007 0.7 0.99 (0.96–1.0)
V40% 0.059 0.05 1.06 (1.0–1.1)
Homogeneity
Index
1.151 0.3 3.2 (0.3–30)
Constant −0.129
Refined model
Age −0.041 0.06 0.96 (0.9–1.0)
Laterality −1.048 0.019 0.35 (0.2–0.8)
Diabetes 2.301 0.036 10 (1–85)
V40% 0.056 0.047 1.1(1.0–1.1)
Constant 0.200
Abbreviations: CI – confidence interval Hosmer and Lemeshow test refined
model χ2 (7) = 6.056, p = 0.553. Pseudo-R2 = 0.14 to 0.18. aOdds ratio per unit
increase in variable or for bilateral radiation and being non-diabetic
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Pak and colleagues suggest that concurrent neurotoxic
chemotherapy may contribute to a higher incidence of
LS [13]. The odds ratio for cisplatin on univariate ana-
lysis is 1.23 (95% confidence interval is 0.5 to 2.3). Thus,
we cannot conclude that there is an effect from cisplatin.
It may be that our study was underpowered to detect
such an effect, and there may be a confounding effect of
separate factors linked with cisplatin use such as age,
hypertension and diabetes.
Surprisingly, V20% was significantly lower on univar-
iate analysis in patients with LS, although its effect
was insignificant in the multi-variate model. Con-
versely, V40Gy and V40% were insignificant on univari-
ate analysis but significant according to the logistic
regression model, consistent with previous work [13].
Of note, TomoTherapy plans confer excellent spinal
cord sparing, meaning only 27.3% of all the patients
in our cohort had a partial cord volume receiving
40 Gy or more. Therefore, our V40Gy results should
be interpreted with caution. Mean Dmax in our cohort
was 36.4 Gy compared to 39.1 to 42.5 Gy in similar
studies using VMAT and IMRT respectively [12, 13],
yet more patients in our cohort reported LS than in
these studies. Interestingly, a study on 105 patients
receiving thoracic IMRT for lymphoma reported a
mean Dmax of 33.5 Gy and had an LS incidence of
29% [5], also suggesting factors other than dose may
be important. According to our multi-variate analysis,
age, diabetes, and unilateral neck radiation may be re-
lated factors, although given the sample size and de-
grees of freedom in the model, p-values for all factors
should be considered borderline significant, and inter-
preted with caution.
Patients developing LS were younger than patients
without LS. The difference was insignificant on uni-
variate analysis and binary logistic regression, but
significant in the ordinal regression, suggesting
younger patients have more severe symptoms if they
do develop LS. These findings are not new: Mul and
co-workers found a mean age of 52 in LS patients
compared with 61 in non-LS patients [15], whilst
Leung et al. found a decreased risk in those over 60
[10]. Although younger patients were more likely to
receive cisplatin (p = 0.0017) they were not more
likely to receive a higher maximum or mean SC dose
(r = 0.030 and − 0.203 respectively, Pearson correl-
ation coefficient).
Intriguingly, our data suggest that patients with
diabetes are less likely to develop LS, a previously
unreported finding. It should be noted that 10.2% of
our cohort had diabetes compared to 3.9% and 4.1%
in similar studies [13, 15]. Nine of 13 diabetic pa-
tients in our cohort took metformin (the one dia-
betic patient with LS also took metformin). This
drug has been suggested to have anti-inflammatory
and anti-oxidant neuroprotective effects in mouse
models of MS [25, 26], whilst a significant anti-
inflammatory effect of metformin and pioglitazone
has also been shown in patients with MS and meta-
bolic syndrome [27]. However, more investigation
would be needed to ascertain whether these benefits
are also seen in radiation-induced demyelination.
Lastly, patients with LS were significantly more likely
to have had unilateral neck radiation. A ‘bath and
shower’ effect, whereby radiation tolerance is reduced if
an area of high dose is surrounded by an area of low
dose, was first demonstrated in rat spinal cords [16, 28].
It is hypothesised that low dose radiation prevents oligo-
dendrocyte migration to repair damage, and can alter
gene expression [29, 30]. This effect was sought, but not
found in a previous clinical study [13]. However, Ko and
colleagues observed LS exclusively in patients that re-
ceived unilateral radiotherapy (5 of 33 patients), and
suggest that axial dose inhomogeneity may contribute to
the development of LS [12]. Other authors postulate that
anterior-posterior dose gradients may be significant be-
cause of spinothalamic tract damage [31].
In addition to a relationship between unilateral
neck irradiation and LS, we also found that unilat-
eral neck treatment plans had much more inhomo-
geneous SC dosimetry. Although this inhomogeneity
was not an independent risk factor for LS in the
multi-variate model, this may be due to the close as-
sociation with treatment laterality, and the possibility
of diluted statistical power within the model. Our in-
terpretation of these data are as follows; firstly, to
corroborate previous findings of higher LS risk in
patients undergoing unilateral neck treatment, sec-
ondly to suggest that inhomogeneous SC dose distri-
butions may be a mechanistic factor in this effect,
and finally that a paradoxically rising incidence of
LS may in part be due to the greater SC dose in-
homogeneity that IMRT confers. It is clear however
that understanding of neurological response to com-
plex dose distributions is incomplete.
Conclusion
The incidence of LS in this study remains paradoxic-
ally higher than previously reported, despite modern
IMRT techniques delivering low SC doses. We found
no increased risk from concomitant cisplatin, but
confirmed previously reported higher risk in younger
patients, and with higher volumes of SC receiving
≥40 Gy. Diabetes appeared to reduce risk, and unilat-
eral neck treatment was associated with LS. Greater
SC dose inhomogeneity may explain this finding, but
further work on neurological response to complex
dose distributions is required.
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Additional file
Additional File 1: Figure S1. The relevant question from the clinical
reporting form Shows the question patients were asked to grade severity
of LS from 1 to 4. Figure S2. Maximum spinal cord dose in patients with
unilateral and bilateral neck radiation Box and whisker plot showing no
difference in Dmax for patients with unilateral and bilateral neck radiation.
Figure S3. Dose parameters in patients with no LS symptoms (unshaded,
n = 75), and with LS (shaded, n = 42) A – Dose to spinal cord. B – Volume
of spinal cord receiving 10, 20, 30, and 40 Gy. C – Percentage of spinal
cord receiving 10, 20, 30, and 40 Gy. Figure S4. Dose parameter multi-
collinearity plots. A – V20% vs V30%. B – V20% vs V40% Scatter plots showing
significant multicollinearity between V20% and V30%, but less collinearity
between V20% and V40%. Table S1. Collinearity statistics for models con-
taining V20%, V30%, and V40% Tables showing variance inflation factor and
tolerance statistics for logistic regression models containing A V20%, V30%,
and V40% (high collinearity); and B V20% and V40% (low collinearity). Table
S2. Ordinal logistic regression with highest reported grade of LS as the
dependent variable Logistic regression output showing younger age and
absence of diabetes are significantly associated with higher grade LS.
Table S3. Binary logistic regression with LS vs Non-LS as the dependent
variable, and absolute dose volumes (in cc). Logistic regression output
showing that using absolute volume or percentage volume makes little
difference to the predictive power of the model or the odds ratio for vari-
ables in the refined model. Table S4. Ordinal logistic regression with
highest reported grade of LS as the dependent variable, and absolute
dose volumes (in cc). Logistic regression output showing that using abso-
lute volume or percentage volume makes little difference to the predict-
ive power of the model or the odds ratio for variables in the refined
model. (PDF 234 kb)
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